Shivani Srivastava, PhD

Featured Publications

• Catalysis-Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass

  Zimmerman K*, Liu X*, von Kroge S*, Stabach P, Lester ER, Chu EY, Srivastava S, Somerman MJ, Tommasini SM, Busse B, Schinke T, Carpenter TO, Oheim R, Braddock DT. Catalysis‐Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass. Journal Of Bone And Mineral Research 2020, 37: 1733-1749. PMID: 35773783, PMCID: PMC9709593, DOI: 10.1002/jbmr.4640.

  Peer-Reviewed Original Research

• A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models

  Stabach P, Sims D, Gomez-Bañuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez S, Petri M, Goldman D, Lester E, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira J, Yarema K, Koumpouras F, Andrade F, Braddock D. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight 2024, 9: e177003. PMID: 38888971, PMCID: PMC11383374, DOI: 10.1172/jci.insight.177003.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  Concepts

• Expression kinetics reveal the self-adaptive role of β cells during the progression of diabetes.

  Srivastava S, Pandey H, Tripathi YB. Expression kinetics reveal the self-adaptive role of β cells during the progression of diabetes. Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie 2018, 106: 472-482. PMID: 29990835, DOI: 10.1016/j.biopha.2018.06.168.

  Peer-Reviewed Original Research

• Incretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis.

  Srivastava S, Shree P, Pandey H, Tripathi YB. Incretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis. Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie 2018, 97: 330-338. PMID: 29091882, DOI: 10.1016/j.biopha.2017.10.071.

  Peer-Reviewed Original Research

• GLP 1 Regulated Intestinal Cell's Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes.

  Srivastava S, Pandey H, Singh SK, Tripathi YB. GLP 1 Regulated Intestinal Cell's Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes. Advanced Pharmaceutical Bulletin 2019, 9: 325-330. PMID: 31380261, PMCID: PMC6664108, DOI: 10.15171/apb.2019.039.

  Peer-Reviewed Original Research

• Active phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach.

  Srivastava S, Shree P, Tripathi YB. Active phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach. Journal Of Diabetes And Metabolic Disorders 2017, 16: 46. PMID: 29201861, PMCID: PMC5697100, DOI: 10.1186/s40200-017-0328-0.

  Peer-Reviewed Original Research

• Anti-oxidant, anti-apoptotic, anti-hypoxic and anti-inflammatory conditions induced by PTY-2 against STZ-induced stress in islets.

  Srivastava S, Pandey H, Singh SK, Tripathi YB. Anti-oxidant, anti-apoptotic, anti-hypoxic and anti-inflammatory conditions induced by PTY-2 against STZ-induced stress in islets. Bioscience Trends 2019, 13: 382-393. PMID: 31597821, DOI: 10.5582/bst.2019.01181.

  Peer-Reviewed Original Research

• Pueraria tuberosa as Dipeptidyl-Peptidase-IV Inhibitor Prevents Streptozotocin-Induced Intestinal Stress.

  Srivastava S, Pandey H, Singh SK, Tripathi YB. Pueraria tuberosa as dipeptidyl-peptidase-IV inhibitor prevents streptozotocin-induced intestinal stress. Open Access Macedonian Journal of Medical Sciences. 2021;9(A):28-34.

  Peer-Reviewed Original Research

• Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies

  Srivastava S*, Tyagi A*, Pawar VA*, Khan NH*, Arora K, Verma C, Kumar V. Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies. Immunotargets Ther 2024, 13: 413-433. PMID: 39219644, DOI: 10.2147/ITT.S474659.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

• Immune Modulatory Effects of Ketogenic Diet in Different Disease Conditions

  Srivastava, S*, Pawar, V.A*, Tyagi, A*, Sharma, K.P*, Kumar, V.; Shukla, S.K. Immune Modulatory Effects of Ketogenic Diet in Different Disease Conditions. Immuno 2023, 3, 1-15. https://doi.org/10.3390/immuno3010001

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements